Evidence map›Paper›PMID 30897978›Full record

ReviewExpert opinion on drug delivery2019

Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.

Rafael R Castillo, Daniel Lozano, Blanca González, Miguel Manzano, Isabel Izquierdo-Barba, María Vallet-Regí

Abstract readReview
In one paragraph

Review in Expert opinion on drug delivery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Pooled it
  2. Review
  3. Mesoporous Silica Nanoparticles in Biomedicine: Advances and Prospects.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Novel Antibacterial Agents 2022.Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  18. Article
  19. Review
  20. Review

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rafael R Castilloa Departamento de Química en Ciencias Farmacéuticas, Unidad de Química Inorgánica y Bionorgánica , Universidad Complutense de Madrid , Madrid , Spain.
Daniel Lozanoa Departamento de Química en Ciencias Farmacéuticas, Unidad de Química Inorgánica y Bionorgánica , Universidad Complutense de Madrid , Madrid , Spain.
Blanca Gonzáleza Departamento de Química en Ciencias Farmacéuticas, Unidad de Química Inorgánica y Bionorgánica , Universidad Complutense de Madrid , Madrid , Spain.
Miguel Manzanoa Departamento de Química en Ciencias Farmacéuticas, Unidad de Química Inorgánica y Bionorgánica , Universidad Complutense de Madrid , Madrid , Spain.
Isabel Izquierdo-Barbaa Departamento de Química en Ciencias Farmacéuticas, Unidad de Química Inorgánica y Bionorgánica , Universidad Complutense de Madrid , Madrid , Spain.
María Vallet-Regía Departamento de Química en Ciencias Farmacéuticas, Unidad de Química Inorgánica y Bionorgánica , Universidad Complutense de Madrid , Madrid , Spain.

Funding

European Research Council 694160
6 · The paper itself

Abstract

introductionMesoporous silica nanoparticles (MSNs) are outstanding nanoplatforms for drug delivery. Herein, the most recent advances to turn MSN-based carriers into minimal side effect drug delivery agents are covered. AREAS COVERED: This review summarizes the scientific advances dealing with MSNs for targeted and stimuli-responsive drug delivery since 2015. Delivery aspects to diseased tissues together with approaches to obtain smart MSNs able to respond to internal or external stimuli and their applications are here described. Special emphasis is done on the combination of two or more stimuli on the same nanoplatform and on combined drug therapy. EXPERT OPINION: The use of MSNs in nanomedicine is a promising research field because they are outstanding platforms for treating different pathologies. This is possible thanks to their structural, chemical, physical and biological properties. However, there are certain issues that should be overcome to improve the suitability of MSNs for clinical applications. All materials must be properly characterized prior to their in vivo evaluation; furthermore, preclinical in vivo studies need to be standardized to demonstrate the MSNs clinical translation potential.

Indexed as

Drug Delivery SystemsNanoparticlesAnimalsDrug CarriersHumansPorositySilicon DioxideDrug CarriersSilicon Dioxidebiomedical applicationsMesoporous silica nanoparticlesstimuli-responsive drug deliverytargeting

Identifiers

PMID30897978
PMCPMC6667337

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.